Robert Lorne Hopfner - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Role
Director, 10%+ Owner
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol
EVMN on NYSE
Transactions as of
05 Nov 2025
Net transactions value
$0
Form type
3
Filing time
05 Nov 2025, 20:05:49 UTC
Previous filing
03 Jul 2025
Next filing
12 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopfner Robert Lorne Director, 10%+ Owner C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO /s/ Gregory S. Moss, Attorney-in-Fact 05 Nov 2025 0001551966

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVMN Series Seed Preferred Stock 05 Nov 2025 Common Stock 3,026 By Trust F1, F2
holding EVMN Series Seed Preferred Stock 05 Nov 2025 Common Stock 838,886 By NFLS Delta III Limited F1, F3
holding EVMN Series Seed Preferred Stock 05 Nov 2025 Common Stock 419,441 By Pivotal bioVenture Partners Fund I, L.P. F1, F4
holding EVMN Series A Preferred Stock 05 Nov 2025 Common Stock 324,578 By NFLS Delta III Limited F3, F5
holding EVMN Series A Preferred Stock 05 Nov 2025 Common Stock 908,821 By Pivotal bioVenture Partners Fund I, L.P. F4, F5
holding EVMN Series B Preferred Stock 05 Nov 2025 Common Stock 240,756 By NFLS Delta III Limited F3, F6
holding EVMN Series B Preferred Stock 05 Nov 2025 Common Stock 267,367 By Pivotal bioVenture Partners Fund I, L.P. F4, F6
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 36,812 By NFLS Delta III Limited F3, F7
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 36,812 By Pivotal bioVenture Partners Fund I, L.P. F4, F7
holding EVMN Series C Preferred Stock 05 Nov 2025 Common Stock 294,502 By Pivotal bioVenture Partners Fund II, L.P. F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ("IPO"), all shares of Series Seed Preferred Stock will be converted into shares of Common Stock of the Issuer.
F2 The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F3 Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F4 Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F5 The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
F6 The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F7 The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
F8 Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.